September 10, 2025HaematologicaOpen Access

Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience

View Full Paper

Ask AI

Bookmark

Authors

LCLorenzo CaniAzienda Ospedaliera Citta' della Salute e della Scienza di Torino SSSara A. ScottEmory Healthcare DRDanielle RobertsNorth Medical Center

Discussion

Member takes

Implication

Retrospective analysis shows infection rates in multiple myeloma patients treated with bispecific antibodies, indicating the need for effective prophylactic measures.

Key Points

The cumulative incidence of infections at 5 and 10 months in anti-BCMA patients was 38.6% and 47.9%, while for anti-GPRC5D patients, it was 28.1% and 30.3%.
IVIG administration significantly decreased the risk of severe infections, with a hazard ratio of 0.38 in multivariate analysis.
This study assessed infections in 158 relapsed/refractory multiple myeloma patients receiving bispecific antibody treatments and their associated risks.
Prophylactic measures included IVIG treatment and coverage for herpes zoster and Pneumocystis jirovecii.

Cite This Study

Cani et al. (2025) studied this question.

synapsesocial.com/papers/68c23bd7b210217d6478705b https://doi.org/10.3324/haematol.2025.288187

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows infection rates in multiple myeloma patients treated with bispecific antibodies, indicating the need for effective prophylactic measures.

Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider